One-year mortality of colorectal cancer patients: development and validation of a prediction model using linked national electronic data. by Cowling, Thomas E et al.
1 
One-year mortality of colorectal cancer patients: development and validation 
of a prediction model using linked national electronic data 
Running title: Prediction of one-year colorectal cancer mortality 
Thomas E Cowling1 2, Alexis Bellot3 4, Jemma Boyle1 2, Kate Walker1 2, Angela Kuryba1, Sarah 
Galbraith5, Ajay Aggarwal6, Michael Braun7, Linda D Sharples8, Jan van der Meulen1 2 
1Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK 
2Department of Health Services Research and Policy, London School of Hygiene & Tropical 
Medicine, London, UK 
3Department of Applied Mathematics and Theoretical Physics, University of Cambridge, Cambridge, 
UK 
4Alan Turing Institute, London, UK 
5Department of Palliative Care, Addenbrooke’s Hospital, Cambridge University Hospitals NHS 
Foundation Trust, Cambridge, UK 
6Department of Clinical Oncology, Guy’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust, 
London, UK 
7Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK 
8Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK 
Correspondence to: Thomas E Cowling (thomas.cowling@lshtm.ac.uk). ORCID ID: 
https://orcid.org/0000-0003-1524-4393 
Competing interests: The authors declare no competing interests.
2 
Abstract 
Background: The existing literature does not provide a prediction model for mortality of all 
colorectal cancer patients using contemporary national hospital data. We developed and validated 
such a model to predict colorectal cancer death within 90, 180, and 365 days after diagnosis. 
Methods: Cohort study using linked national cancer and death records. The development population 
included 27 480 patients diagnosed in England in 2015. The test populations were diagnosed in 
England in 2016 (n=26 411) and Wales in 2015-16 (n=3814). Predictors were age, gender, 
socioeconomic status, referral source, performance status, tumour site, TNM stage, and treatment 
intent. Cox regression models were assessed using Brier scores, c-indices, and calibration plots. 
Results: In the development population, 7.4%, 11.7%, and 17.9% of patients died from colorectal 
cancer within 90, 180, and 365 days after diagnosis. T4 versus T1 tumour stage had the largest 
adjusted association with the outcome (HR 4.67; 95% CI: 3.59–6.09). C-indices were 0.873–0.890 
(England) and 0.856–0.873 (Wales) in the test populations, indicating excellent separation of 
predicted risks by outcome status. Models were generally well calibrated. 
Conclusions: The model was valid for predicting short-term colorectal cancer mortality. It can 
provide personalised information to support clinical practice and research.  
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Background 
In 2018, colorectal cancer was the third most incident cancer and caused the second largest number of 
cancer deaths in high-income countries.1,2 It is a heterogeneous disease with varied presentations and 
large differences in prognosis. Considering the cancer stage alone, one-year net survival for localised 
and metastatic cancer varies from 96% to 55%, respectively, in the United States.3 
Clinical prediction models combine multiple prognostic factors to estimate individualised risks of 
outcomes for each patient.4,5 These risk predictions have many uses. In colorectal cancer research, 
prediction models have been used to examine prognosis in clinical trials,6 to control for confounding 
in observational studies,7 and to assess the added prognostic value of biomarkers.8 In clinical practice, 
they may be used to inform treatment decisions and to communicate prognosis to patients, in line with 
the aims of personalised medicine and shared decision-making.9 
In the absence of high-quality prediction models, clinicians’ predictions of cancer survival may be 
inaccurate, non-transparent, and difficult to explain to patients.10-12 Existing models for colorectal 
cancer mortality have focused on selected populations recruited to clinical trials (such as stage III and 
IV groups)6,13,14, risks after surgery or chemotherapy,15,16 or long-term survival using primary care 
data.17 A recent systematic review18 did not identify any models to predict mortality for all colorectal 
cancer patients using contemporary national hospital data. 
In this study, our objective was to develop and validate a prediction model for death from colorectal 
cancer within three, six, and twelve months after diagnosis. To do this, we analysed national 




The National Bowel Cancer Audit collects data on adults (aged 18 years or over) newly diagnosed 
with colorectal cancer (International Classification of Diseases 10th Revision (ICD-10) codes: C18-
2019) in England and Wales.20 These data are entered into electronic record systems by hospital staff 
and later combined into a pooled national dataset by the National Health Service (NHS). We analysed 
data for patients whose date of diagnosis was from January 2015 to December 2016. 
We defined one population to develop the prediction model and two separate populations to test the 
performance of this model. The eligible population used for model development included patients 
who were diagnosed in England in 2015 (n=28 505 patients). The first test population included 
patients who were diagnosed in England in 2016 (n=28 216 patients). The second test population 
included patients who were diagnosed in Wales in 2015 or 2016 (n=3861 patients). 
Outcome 
The outcome was death from colorectal cancer as identified from official death records provided by 
the Office for National Statistics.21 We defined death from colorectal cancer using relevant ICD-10 
codes recorded as the ‘underlying cause of death’ (see Supplement S1). The underlying cause is ‘the 
disease or injury which initiated the train of morbid events leading directly to death’.22 
Time to death was defined as the number of days between the date of diagnosis (as recorded in the 
National Bowel Cancer Audit dataset) and the date of death from colorectal cancer (as recorded in 
Office for National Statistics mortality data). The date of diagnosis was ‘the date when cancer was 
confirmed or diagnosis agreed’, which is typically the date of the pathology report that confirmed 
cancer. Patients who died from other causes were censored on the date of death. Patients alive as of 1 
January 2018 were censored on that date, providing at least 365 days of follow-up for all patients. 
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Records from the National Bowel Cancer Audit and Office for National Statistics datasets were 
combined using deterministic linkage based on each patient’s unique NHS number, date of birth, 
gender, and postcode. From the 60 582 eligible patients (in both development and test sets), the final 
sample size was 57 705 patients (27 480 in the development population; 26 411 in the England test 
population; and 3814 in the Wales test population). Supplement S2 provides the sample flow chart. 
Distributions of variables were similar for the linked and unlinked patients (Supplement S3). 
Predictor variables 
We used ten variables from the National Bowel Cancer Audit dataset as predictor variables: age, 
gender, socioeconomic status, source of referral, performance status, tumour site, TNM (tumour, 
node, metastasis) stage at diagnosis, and treatment intent. All variables were recorded in electronic 
data systems around the time of the first meeting between clinicians to discuss patients’ treatment 
after diagnosis. We selected these predictors a priori to include variables recorded around the time of 
diagnosis that had relatively complete data (≥80% of values non-missing). 
Patient age was coded as a continuous variable defined as the number of complete years between the 
dates of birth and diagnosis. Gender was male/female. Socioeconomic status was defined as the 
national rank of a patient’s area of residence according to the Index of Multiple Deprivation23; the 
mean population size of these areas was 1500.23 To aid interpretation, these ranks were linearly 
rescaled to have a median of zero and lower and upper quartiles of -1 and +1 respectively.24 
The source of referral for investigation of suspected cancer had five categories: emergency hospital 
admission, urgent care/emergency department visit, primary care, national screening programme, and 
‘other’ (e.g. a separate outpatient clinic). Performance status was defined by five categories of the 
Eastern Cooperative Oncology Group score (ranging from ‘fully active’ to ‘completely disabled’).25 
Tumour site was one of nine ICD-10 codes indexed under C18-20. T, N, and M stages of the cancer 
were defined by the TNM Classification of Malignant Tumours 5th Edition.26 The treatment intent had 
three categories: curative, non-curative, and no active cancer treatment. 
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All ten predictor variables were defined using the National Bowel Cancer Audit dataset. The original 
(incomplete) data were used to calculate descriptive statistics for each variable. To account for 
missing values of predictors, we used multiple imputation with chained equations to generate 40 
complete datasets (see Supplement S4 for details). All analysis of associations between the outcome 
and predictors was done using these 40 imputed datasets. We pooled model estimates and 
performance measures across the datasets to produce the final results.27 
Statistical analysis 
We used Cox proportional hazards regression28 to estimate associations between predictor variables 
and the hazard of colorectal cancer death. Deaths from other causes were treated as censoring events. 
All predictors entered the regression model simultaneously. We fitted linear associations with the 
outcome for age and socioeconomic status, as non-linear transformations fitted by a multivariable 
fractional polynomial algorithm29-31 were well approximated by linear relationships. 
We assessed model performance at 90, 180, and 365 days after diagnosis. Overall model performance 
was measured using Brier scores.32 These scores were calculated from the mean squared differences 
between predicted probabilities of colorectal cancer death within a given time period and the observed 
death status. We scaled these scores from 0–100% (0% if non-informative and 100% if perfect).33 
To assess discrimination, we calculated the c-index.34 This indicates the proportion of all pairs of 
patients whose survival times could be ordered such that the patient with the lower predicted risk of 
colorectal cancer death survived longer.24 C-indices equal one for perfect models and 0.5 for random 
predictions. To assess model calibration, we plotted the predicted risks of colorectal cancer death 
against the actual observed risks, using the loess smoother to estimate the calibration curve.24 
We assessed the internal validity of the model using 10-fold cross-validation and calculated mean 
values of the performance measures across the ten folds. We tested the performance of the model in 
two other populations: patients diagnosed in England in 2016 and in Wales in either 2015 or 2016. 
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Sensitivity analyses 
Three sensitivity analyses tested the specification of the model and its performance, as detailed in 
Supplement S5. These added interaction terms between key predictors, added a comorbidity score and 
the number of unplanned admissions in the past year as predictor variables, and assessed whether 
censoring of surviving patients at 365 days affected the associations estimated. 
Data preparation was done using Stata (v15) and R (v3.5) was used for all statistical analysis. 
Results 
In the population used to develop the prediction model, the percentages of patients who died from 
colorectal cancer were 7.4% (within 90 days), 11.7% (180 days), and 17.9% (365 days). These 
percentages were similar in the England test population but slightly greater in the Wales test 
population (Table 1). The Wales population had greater percentages of patients who were referred for 
diagnostic investigations after an emergency admission (29.0% vs. 13.0% in the development 
population) and who had metastases (25.6% vs. 22.1%). Most patients in each population were treated 
with curative intent (73.3% to 74.1%) (Table 2). 
Missing values were most common for the performance status of the patient (16.8%) and the T and N-
stages of the cancer (19.2% and 17.0%; Table 2). Data fields were complete across all variables for 
61.5% of patients. These patients were more likely to be treated with curative intent (76.6% vs. 
67.5%) and to survive until the end of follow-up (70.6% vs. 61.5%) than patients who had at least one 
predictor variable with a missing value (Supplement S6). 
After multiple imputation of missing values, risks of colorectal cancer death were greatest for patients 
who had metastatic disease, had a treatment plan with non-curative intent or no active cancer 
treatment, or had an unfavourable performance status (Table 3). The risk of cancer death within 365 
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days was more than 50% for three patient groups: patients in the two worst performance status 
categories (50.3% and 58.3%) and patients with a non-curative treatment intent (51.9%). 
In the multivariable model including all predictor variables, the greatest relative difference in the 
hazard of colorectal cancer death was between the T4 and T1 stages (hazard ratio (HR) = 4.67; 95% 
confidence interval (CI): 3.59 to 6.09). Compared to patients with a curative treatment intent, the 
hazard of colorectal cancer death was 3.85 times greater for patients whose treatment plan was non-
curative (HR = 3.85, 95% CI: 3.60 to 4.11) or did not include active cancer treatment (HR = 3.85, 
95% CI: 3.52 to 4.21). Outcomes were similar between the non-curative and no active cancer 
treatment groups (HR = 1.00, 95% CI: 0.92 to 1.09) (Table 3). 
Predicted probabilities of colorectal cancer death varied widely within treatment intent categories. In 
the England test population, the 10th and 90th percentiles of predicted risks within 365 days were 1.7% 
and 12.9% for patients treated with curative intent, 23.8% and 88.8% for patients with a non-curative 
intent, and 16.3% and 89.6% for patients with no active cancer treatment planned. 
Model performance 
The probabilities of colorectal cancer death predicted by the model were well-calibrated with the 
observed proportions of patients that died, in both England and Wales test populations (Figure 1). 
The model typically predicted very low risks of colorectal cancer death for patients who did not 
experience this outcome (Figure 2). The predicted risks were generally much greater for patients who 
did die from colorectal cancer, particularly for the 365-day outcome period. As a result, the predicted 
probabilities of colorectal cancer death were well separated between patients who did and did not 
have this outcome (Figure 2). This was reflected in large values of the c-index, ranging from 0.873 to 
0.890 and 0.856 to 0.873 in the England and Wales test populations, respectively (Table 4). 
The overall performance of the model as measured by the scaled Brier score was best for the 365-day 
period, followed by the 180 then 90-day periods (Table 4). For the 365-day period in the England test 
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population, the Brier score was improved by 40.0% compared to if the overall risk of colorectal 
cancer death had been used as the predicted probability for all patients, indicating a large 
improvement in prediction ability when using the model (versus no model). 
Sensitivity analyses 
In the sensitivity analyses, interaction terms between patient age, M-stage, and treatment intent did 
not improve model performance (maximum absolute difference in c-index or Brier score vs. main 
analysis = 0.001). Results were also similar when each patient’s history of comorbidities and 
unplanned hospitalisations were added as predictors (maximum absolute difference = 0.002). When 
patients who were alive 365 days after diagnosis were censored at this time point, predictor effects 
were similar to those in the main analysis (range of relative differences in HRs: 0.97 to 1.08). 
Discussion 
The model developed was valid for predicting death from colorectal cancer within three, six, and 
twelve months after diagnosis in England and Wales. The model discriminated very well between 
patients who did and did not die from colorectal cancer, such that the former group typically had 
much higher predicted probabilities of death. These predictions were well calibrated with observed 
outcomes. The T-stage of the tumour had the largest adjusted association with the risk of death, 
followed by the treatment intent and performance status of the patient. 
No single variable alone had a high positive predictive value for colorectal cancer death. For example, 
just over half of patients (51%) who did not have a curative treatment intent died within 365 days. 
Predicted risks of death varied widely across patients who did not have a curative intent. This wide 
variation also existed for patients who did have a curative treatment plan. 
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Strengths and limitations 
We used large, national datasets to develop a new model and examine its temporal and geographic 
validity in whole populations from two countries. The data used for predictor variables were entered 
as part of routine care processes and therefore represent information available to clinicians in practice 
around the time of decision-making. We used cause of death information from official death records 
to distinguish colorectal cancer deaths from other deaths, and we were able to measure these 
outcomes for at least one year after diagnosis for all patients. Though the patients in the test sets were 
similar to those in the development set, the differences in the type of referrals and TNM stages 
between England and Wales provided a reasonable test of external validity. 
The model would likely be improved if further information about the cancer was available, such as the 
sites of any metastases or possibly molecular data, as well as additional characteristics of patients 
(such as frailty) and their cancer care. This may help to predict greater probabilities of colorectal 
cancer death for patients who experienced this outcome. Some uncertainty in prognosis may reflect 
the biological development of cancer and the possibility of treatment-related complications. 
Detailed assessment of patients’ overall morbidity, particularly for older patients, could be used to 
contextualise predictions of cancer mortality in terms of overall life expectancy. However, the overall 
risk of dying from causes other than colorectal cancer within one year after diagnosis was only 4%, so 
other causes of mortality in this period may be less relevant to treatment decisions for most patients.  
Differences in data collection or population characteristics may limit the generalisability of the model 
to other countries. Estimates of one-year survival for colorectal cancer can differ markedly between 
high-income countries, such as 78% in England and 84% in Sweden in 2010-12.35 The model may 
need to be re-calibrated when used elsewhere if the survival differences are unexplained by 
differences in the distributions of predictors. However, despite survival in Wales being somewhat 
worse than in England in the current study, model calibration remained acceptable. Most predictors 
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used have standard international definitions. We rescaled the measure of socioeconomic status so that 
it might approximate similarly rescaled measures in other settings. 
In order to avoid the possibility that any racial biases in access to treatment are reinforced by the 
prediction model, we did not consider patient ethnicity as a predictor.36 This is in line with most 
clinical prediction models.37 Prognostic factors such as lymphovascular invasion, surgical margin 
status, and definitive treatment were not included in the model as they are typically unknown around 
the time of diagnosis and were not relevant to all patients (some of whom do not receive surgery). 
Missing data will have biased results if data were ‘missing not at random’, which multiple imputation 
cannot address. The extent of this bias cannot be ascertained from observed data, but each predictor 
had less than 20% of values missing, thus reducing the potential bias. National Bowel Cancer Audit 
records could not be linked to Office for National Statistics death records for 4.4% of eligible patients; 
distributions of predictor variables were similar between the linked and unlinked groups of patients 
but some bias due to linkage problems cannot be ruled out. 
The 5th edition of the TNM system used in the analysis has been superseded by the 8th edition in the 
U.K., which will affect the N stage of some (but relatively few) patients. 
Relation to existing literature 
A previous study17 used primary care records and cancer registry data to develop a prediction model 
for longer-term survival (1, 5, and 10-year) of colorectal cancer patients in England. This model did 
not include several variables that are routinely recorded in clinical team meetings shortly after 
diagnosis such as the referral source, performance status, separate TNM stages, and treatment intent. 
The c-index of 0.873 attained by our model for predicting 365-day cancer mortality in England is 
much greater than that reported for one-year mortality (from all causes) in the previous study (0.795 
for men and 0.807 for women17). This indicates a large increase in performance (closer to the perfect 
c-index of 1), especially as c-indices are relatively insensitive to improvements in model fit.38 
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A systematic review18 reported several prediction models developed for mortality in subgroups of 
colorectal cancer patients, such as patients with stage III6 or metastatic13,14 cancer, or for post-
treatment mortality.15,16 None of these models were developed to predict mortality for all colorectal 
cancer patients using contemporary national hospital data. A previous study7 by our group used linked 
National Bowel Cancer Audit and Office for National Statistics death records to develop a risk-
adjustment model for 90-day postoperative mortality. This model used similar predictors to the model 
presented here and showed good discrimination (c-index=0.799) and calibration; the c-index may 
have been lower in this surgical cohort partly due to the population being more homogeneous. 
Implications for research and practice 
The predictor information used in the model is recorded electronically as part of routine practice in 
England and Wales, typically during clinical team meetings where patient care is planned. Patients’ 
risks of death within three, six, and twelve months could be automatically calculated in these meetings 
without additional data entry. Supplement S7 gives the formula for calculating predicted probabilities 
of colorectal cancer death within 90, 180, and 365 days after diagnosis. 
The external validity of the model should be tested further before being used outside of England and 
Wales, possibly in combination with well-established methods for updating prediction models when 
used in new settings.39 Ideally, the effects of the model on decision-making and patient outcomes 
would also be evaluated in future research (though such impact studies are rare40). 
The model’s predictions could be used to provide accurate prognostic information to patients, so that 
they can make informed decisions together with clinicians. The risk predictions may also help to 
prioritise patients for specialist palliative care services,41,42 given the wide range of predicted risks for 
patients without a curative treatment intent. The predictions also varied widely for those with a 
curative intent, which may help to inform the intensity of related treatment. Finally, the model could 
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Test population - 
England 
Test population - 
Wales 
Number of patients 27 480 26 411 3814 
CRC death within, n (%)    
90 days 2024 (7.4) 1862 (7.1) 362 (9.5) 
180 days 3210 (11.7) 2978 (11.3) 540 (14.2) 
365 days 4926 (17.9) 4659 (17.6) 820 (21.5) 
Other death within, n (%)    
90 days 483 (1.8) 467 (1.8) 83 (2.2) 
180 days 762 (2.8) 677 (2.6) 117 (3.1) 
365 days 1139 (4.1) 1039 (3.9) 158 (4.1) 
Median follow-up (IQR), 
days* 
908 (818 to 999) 544 (452 to 636) 705 (527 to 906) 
 
CRC colorectal cancer, IQR interquartile range 
*Calculated using the reverse Kaplan-Meier method 
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Test population – 
England (n=26 411) 
Test population – 
Wales (n=3814) 
Median age (years; IQR)* 72 (63 to 80) 72 (63 to 80) 72 (64 to 80) 
Gender, n (%)    
Male (vs. female) 15 505 (56.4) 15 101 (57.2) 2209 (57.9) 
Missing 7 12 0 
Median socioeconomic status 
(IQR)† 
0.2 (-0.8 to 1.1) 0.3 (-0.7 to 1.1) -1.9 (-1.9 to -1.8)** 
Referral source, n (%)    
Emergency admission 3542 (13.0) 3224 (12.4) 1092 (29.0) 
Urgent care/ED visit 741 (2.7) 768 (3.0) 55 (1.5) 
Screening 2701 (10.0) 2749 (10.6) 398 (10.6) 
Primary care 15 227 (56.1) 14 549 (56.0) 1871 (49.6) 
Other 4943 (18.2) 4689 (18.1) 354 (9.4) 
Missing 326 432 44 
Performance status, n (%)‡    
0 (fully active) 10 014 (43.9) 10 234 (45.8) 1217 (42.5) 
1 7166 (31.4) 6770 (30.3) 924 (32.2) 
2 3505 (15.4) 3285 (14.7) 462 (16.1) 
3 1793 (7.9) 1729 (7.7) 234 (8.2) 
4 (completely disabled) 340 (1.5) 313 (1.4) 29 (1.0) 
Missing 4662 4080 948 
Tumour site, n (%)    
Caecum 4087 (14.9) 3885 (14.7) 574 (15.1) 
Ascending colon 3043 (11.1) 2908 (11.0) 416 (10.9) 
Hepatic flexure 1083 (3.9) 1059 (4.0) 167 (4.4) 
Transverse colon 1783 (6.5) 1725 (6.5) 232 (6.1) 
Splenic flexure 688 (2.5) 671 (2.5) 104 (2.7) 
Descending colon 946 (3.4) 980 (3.7) 118 (3.1) 
Sigmoid colon 6364 (23.2) 6189 (23.4) 842 (22.1) 
Rectosigmoid junction 1545 (5.6) 1477 (5.6) 226 (5.9) 
Rectum 7941 (28.9) 7517 (28.5) 1135 (29.8) 
Missing 0 0 0 
T-stage, n (%)    
1 1338 (6.1) 1291 (6.0) 142 (4.3) 
2 4387 (20.0) 4275 (20.0) 630 (19.2) 
3 11 399 (51.9) 11 081 (51.8) 1670 (50.9) 
4 4847 (22.1) 4731 (22.1) 840 (25.6) 
Missing 5509 5033 532 
N-stage, n (%)    
0 10 790 (47.8) 10 554 (48.0) 1532 (46.1) 
1 7657 (33.9) 7566 (34.4) 1108 (33.4) 
2/3 4137 (18.3) 3865 (17.6) 682 (20.5) 
Missing 4896 4426 492 
M-stage, n (%)    
0 17 975 (77.9) 17 853 (78.6) 2413 (74.4) 
1 5094 (22.1) 4861 (21.4) 832 (25.6) 
Missing 4411 3697 569 
Treatment intent, n (%)    
Curative 19 078 (73.3) 18 089 (73.7) 2406 (74.1) 
Non-curative 5440 (20.9) 4869 (19.8) 722 (22.2) 
No active cancer treatment 1508 (5.8) 1601 (6.5) 118 (3.6) 
Missing 1454 1852 568 
ED emergency department, IQR interquartile range 
Number of patients with no missing values across all populations = 35 472 (61.5%). 
*Age range was 18 to 104. †Rescaled national rank of the area in which a patient resided (0 is the median; -1 is 
the lower quartile, more deprived; 1 is the upper quartile, less deprived). ‡Measured on the Eastern Cooperative 
Oncology Group (ECOG) scale. **Values not comparable to England values due to differences in scales 
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Table 3. Univariable and multivariable associations between the outcome and predictor variables in 






















Age (per 10 years) - - - 1.39 (1.37 to 1.42) 1.21 (1.18 to 1.23) 
Gender      
Male 6.8 11.0 16.8 1 1 
Female 8.0 12.6 19.3 1.09 (1.05 to 1.14) 1.02 (0.98 to 1.07) 
Socioeconomic status* - - - 0.92 (0.90 to 0.93) 0.96 (0.95 to 0.98) 
Referral source      
Emergency admission 18.1 25.0 34.5 1 1 
Primary care 6.0 10.3 16.8 0.47 (0.44 to 0.49) 0.73 (0.69 to 0.78) 
Urgent care/ED visit 15.6 22.0 31.1 0.88 (0.78 to 0.99) 0.98 (0.86 to 1.12) 
Screening 0.7 1.3 2.2 0.09 (0.08 to 0.11) 0.33 (0.29 to 0.39) 
Other 6.2 10.4 16.3 0.46 (0.43 to 0.49) 0.75 (0.69 to 0.81) 
Performance status†      
0 (fully active) 2.3 4.5 8.5 1 1 
1 5.2 9.3 15.9 1.73 (1.63 to 1.84) 1.20 (1.13 to 1.28) 
2 11.3 17.8 26.9 2.95 (2.76 to 3.15) 1.53 (1.42 to 1.66) 
3 28.3 39.7 50.3 6.99 (6.51 to 7.51) 2.34 (2.14 to 2.55) 
4 (completely disabled) 39.7 48.8 58.3 10.04 (8.68 to 11.60) 3.37 (2.87 to 3.96) 
Tumour site      
Caecum 11.0 16.7 25.1 1 1 
Ascending colon 7.8 12.4 19.9 0.77 (0.71 to 0.84) 0.92 (0.84 to 1.00) 
Hepatic flexure 9.9 15.4 23.4 0.92 (0.82 to 1.03) 1.14 (1.01 to 1.29) 
Transverse colon 10.0 16.3 23.0 0.89 (0.81 to 0.98) 1.08 (0.98 to 1.19) 
Splenic flexure 9.3 12.5 18.2 0.73 (0.63 to 0.84) 0.88 (0.76 to 1.03) 
Descending colon 10.3 14.2 18.9 0.77 (0.68 to 0.88) 0.92 (0.80 to 1.05) 
Sigmoid colon 6.7 10.7 16.1 0.66 (0.62 to 0.71) 0.81 (0.75 to 0.87) 
Rectosigmoid junction 7.3 11.9 18.3 0.73 (0.66 to 0.81) 0.85 (0.76 to 0.94) 
Rectum 4.5 7.7 12.9 0.61 (0.57 to 0.65) 0.79 (0.73 to 0.85) 
T-stage      
1 0.8 1.4 2.1 1 1 
2 2.5 3.8 6.1 2.93 (2.24 to 3.84) 2.03 (1.55 to 2.66) 
3 6.2 9.9 15.8 7.30 (5.66 to 9.41) 3.02 (2.32 to 3.93) 
4 16.0 25.2 37.2 17.80 (13.80 to 22.96) 4.67 (3.59 to 6.09) 
N-stage      
0 4.2 6.5 10.4 1 1 
1 8.4 13.4 20.5 1.98 (1.87 to 2.10) 1.15 (1.08 to 1.23) 
2/3 13.5 21.5 32.1 3.34 (3.15 to 3.56) 1.52 (1.42 to 1.64) 
M-stage      
0 3.0 5.0 8.7 1 1 
1 22.6 34.9 49.9 7.45 (7.09 to 7.82) 2.81 (2.62 to 3.02) 
Treatment intent      
Curative 1.5 2.7 5.9 1 1 
Non-curative 23.0 36.3 51.9 10.74 (10.22 to 11.28) 3.85 (3.60 to 4.11) 
No active cancer treatment 23.8 34.1 45.3 8.41 (7.80 to 9.06) 3.85 (3.52 to 4.21) 
 
CI confidence interval, CRC colorectal cancer, ED emergency department, HR hazard ratio 
*National rank of the area in which a patient resided (1 unit increase equals difference between quartiles of ranks) 
†Measured on the Eastern Cooperative Oncology Group (ECOG) scale  
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Test population - 
England 
Test population - 
Wales 
Scaled Brier score (%)    
90 days 23.5 23.7 24.1 
180 days 32.6 32.4 32.1 
365 days 39.5 40.0 40.1 
c-index    
90 days 0.885 0.890 0.873 
180 days 0.882 0.885 0.867 
365 days 0.870 0.873 0.856 
 
Scaled Brier scores range from 0% to 100% with larger scores indicating better performance 




Figure 1. Calibration plots for predicted probabilities of colorectal cancer death within 90, 180, and 
365 days after diagnosis, in the England and Wales test populations 
 
Note: The coloured lines represent the smoothed relationships between the observed and predicted risks of colorectal 
cancer death. The black dotted 45° line represents the ideal relationship showing perfect calibration. 
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Figure 2. Boxplots comparing predicted probabilities of colorectal cancer death by outcome status 
within 90, 180, and 365 days after diagnosis, in the England and Wales test populations 
 
Note: Boxes are drawn from the lower to upper quartile of predicted probabilities with a white horizontal line at the 
median value. Annotated values and black dots correspond to mean values. Whiskers are drawn to the most extreme 
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Supplement S1. ICD-10 codes used to identify deaths from colorectal cancer 
ICD-10 code Description 
C18 Malignant neoplasm of colon 
C19 Malignant neoplasm of rectosigmoid junction 
C20 Malignant neoplasm of rectum 
C26.0 Malignant neoplasm of other and ill-defined digestive organs: intestinal tract, part 
unspecified 
C26.9 Malignant neoplasm of other and ill-defined digestive organs: ill-defined sites 
within the digestive system 
C76.2 Malignant neoplasm of other and ill-defined sites: abdomen 
C77 Secondary and unspecified malignant neoplasm of lymph nodes 
C78 Secondary malignant neoplasm of respiratory and digestive organs 
C79 Secondary malignant neoplasm of other and unspecified sites 
D37.4 Neoplasm of uncertain or unknown behaviour of oral cavity and digestive organs: 
colon 
D37.5 Neoplasm of uncertain or unknown behaviour of oral cavity and digestive organs: 
rectum 
D37.7 Neoplasm of uncertain or unknown behaviour of oral cavity and digestive organs: 
other digestive organs 
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Adults newly diagnosed with colorectal cancer (C18-
20) in England and Wales and recorded in the 
National Bowel Cancer Audit 
(1 January 2015 to 31 December 2016) 
n = 61,537 
Patients with cancer of the appendix 
(n = 955) 
Patients whose cancer audit data could not be 
linked to mortality data 
(n = 2,656) 
 
Patients whose date of death was before or 
the same as their date of diagnosis 
(n = 221) 
Development population: 
Eligible patients diagnosed 
with colorectal cancer in 
England in 2015 
n = 27,480 
Test population 1: 
Eligible patients diagnosed 
with colorectal cancer in 
England in 2016 
n = 26,411 
Test population 2: 
Eligible patients diagnosed 
with colorectal cancer in Wales 
in 2015 and 2016 
n = 3,814 
Eligible patients newly diagnosed with colorectal 
cancer in England and Wales 
(1 January 2015 to 31 December 2016) 
n = 60,582 
Died from colorectal cancer 
within one year: n = 4,926 
Died from colorectal cancer 
within one year: n = 4,659 
Died from colorectal cancer 
within one year: n = 820 
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Supplement S3. Descriptive statistics for predictor variables by linkage of the National Bowel Cancer 






Median age (years; IQR)* 72 (63 to 80) 73 (65 to 80) 
Gender (%)     
Male (vs. female) 56.9 54.3 
Median socioeconomic status (IQR)† 0.1 (-1.0 to 1.1) 0.1 (-0.8 to 1.0) 
Referral source (%)     
Emergency admission 13.9 14.4 
Urgent care/ED visit 2.8 2.6 
Screening 10.2 9.1 
Primary care 55.5 55.8 
Other 17.6 18.1 
Performance status‡ (%)     
0 (fully active) 44.6 43.0 
1 30.9 31.6 
2 15.2 15.7 
3 7.9 7.8 
4 (completely disabled) 1.5 1.9 
Tumour site (%)     
Caecum 14.8 16.6 
Ascending colon 11.0 10.8 
Hepatic flexure 4.0 4.2 
Transverse colon 6.5 6.9 
Splenic flexure 2.6 3.3 
Descending colon 3.5 4.0 
Sigmoid colon 23.2 22.5 
Rectosigmoid junction 5.6 5.2 
Rectum 28.7 26.5 
T-stage (%)     
1 5.9 6.1 
2 19.9 19.9 
3 51.7 51.6 
4 22.4 22.5 
N-stage (%)     
0 47.8 47.9 
1 34.1 35.1 
2/3 18.1 17.0 
M-stage (%)     
0 77.9 78.4 
1 22.1 21.6 
Treatment intent (%)     
Curative 73.4 75.7 
Non-curative 20.6 18.1 
No active cancer treatment 6.0 6.2 
*Age range was 18 to 104. †Rescaled national rank of the area in which a patient resided (0 is the median; -1 is 
the lower quartile; 1 is the upper quartile). ‡Measured on the Eastern Cooperative Oncology Group (ECOG) 
scale. ED: emergency department. 
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Supplement S4. Methods for imputed datasets 
We applied multiple imputation using chained equations to predict missing values of predictor 
variables.1 For each of these variables, all other predictors, colorectal cancer death status and the 
Nelson-Aalen estimate of the cumulative baseline hazard were included in the imputation model.2 The 
imputation method was predictive mean matching for continuous variables, logistic regression for 
binary variables, and polytomous regression for categorical variables with more than two categories. 
We generated 40 complete imputed datasets for each population, following guidance to use at least as 
many imputed datasets as the percentage of observations with incomplete data.3 Imputation was done 
separately for each population to avoid introducing artificial correlations across populations. 
Estimates from Cox proportional hazards regression in each imputed dataset were pooled using 
Rubin’s rules.4 When assessing the internal validity of the model using 10-fold cross-validation, we 
calculated the medians of the cross-validated estimates of the Brier score and c-index in each imputed 
dataset.5 As there were 40 complete imputed datasets for the development population and each test 
population, there were 1,600 (40 x 40) unique combinations of datasets for each test population. 
When assessing external validity, we tested model performance for each of these combinations, then 
calculated the medians of the Brier score and c-index across the 1,600 combinations. 
For the calibration plots, we calculated the mean of the complementary log-log transformation of the 
probability estimated for each patient across the 1,600 combinations.5 The back-transformed means 
were then plotted against the observed risks. 
References: 
1. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. Journal of 
Statistical Software 2011;45(3):67. 
2. White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med 2009;28(15):1982-98. 
3. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for 
practice. Stat Med 2011;30(4):377-99. 
4. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: Wiley; 1987. 
5. Marshall A, Altman DG, Holder RL, Royston P. Combining estimates of interest in prognostic modelling 
studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol 2009;9:57.  
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Supplement S5. Sensitivity analyses 
We examined whether adding an interaction term between patient age and M-stage improved model 
performance, as this interaction was predictive of 90-day postoperative mortality in a similar dataset.1 
We also added interactions between age and treatment intent and between M-stage and treatment 
intent in this model, to allow treatment to moderate key patient characteristics. 
We assessed the benefit of adding two extra variables as predictors: a comorbidity score and the 
number of unplanned hospital admissions in the year before diagnosis. These variables were limited to 
sensitivity analyses as they are not available from the same dataset as the other predictors so would be 
more difficult to implement practically. The comorbidity score was a weighted number of 
comorbidities, based on 28 non-cancer comorbidities2 and their established weights.3 To generate the 
scores, we linked National Bowel Cancer Audit records to routine hospital records of inpatient 
admissions (Hospital Episode Statistics4). We used ICD-10 codes5 to identify each comorbidity in the 
year before diagnosis. The number of unplanned admissions was derived from the same dataset. 
The Cox proportional hazards model assumes that the hazard ratios are constant over the follow-up 
period. We explored whether different follow-up periods affected the hazard ratios estimated by 
censoring survival times beyond 365 days at 365 days and re-estimating the model. 
References: 
1. Walker K, Finan PJ, van der Meulen JH. Model for risk adjustment of postoperative mortality in patients with 
colorectal cancer. Br J Surg 2015;102(3):269-80. 
2. Elixhauser A, Steiner C, Harris DR, Coffey RN. Comorbidity measures for use with administrative data. Med 
Care 1998;36(1):8-27. 
3. van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A Modification of the Elixhauser Comorbidity 
Measures into a Point System for Hospital Death Using Administrative Data. Med Care 2009;47(6):626-33. 
4. NHS Digital. Hospital Episode Statistics (HES). Available from: https://digital.nhs.uk/data-and-
information/data-tools-and-services/data-services/hospital-episode-statistics.  
5. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining 
comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43(11):1130-9.  
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Supplement S6. Comparison of patients with completely observed data for all variables and patients 
with missing data for one or more variables 
 Completely observed data Missing data 
Number (%) of patients 35 472 (61.5) 22 233 (38.5) 
Median survival/follow-up time (IQR) 597 (406 to 823) 563 (318 to 816) 
Status at follow-up end, n (%)   
Survived 25 053 (70.6) 13 679 (61.5) 
Colorectal cancer death 8524 (24.0) 6861 (30.9) 
Other death 1895 (5.3) 1693 (7.6) 
Median age (years; IQR)* 72 (63 to 80) 73 (64 to 81) 
Gender, n (%)   
Male (vs. female) 20 480 (57.7) 12 335 (55.5) 
Median socioeconomic status (IQR)† 0.1 (-1.0 to 1.1) 0.0 (-1.0 to 1.0) 
Referral source, n (%)   
Emergency admission 4297 (12.1) 3561 (16.6) 
Urgent care/ED visit 772 (2.2) 792 (3.7) 
Screening 3704 (10.4) 2144 (10.0) 
Primary care 20 706 (58.4) 10 941 (51.1) 
Other 5993 (16.9) 3993 (18.6) 
Performance status, n (%)‡   
0 (fully active) 16 366 (46.1) 5099 (40.7) 
1 10 985 (31.0) 3875 (30.9) 
2 5309 (15.0) 1943 (15.5) 
3 2425 (6.8) 1331 (10.6) 
4 (completely disabled) 387 (1.1) 295 (2.4) 
Tumour site, n (%)   
Caecum 5069 (14.3) 3477 (15.6) 
Ascending colon 3974 (11.2) 2393 (10.8) 
Hepatic flexure 1386 (3.9) 923 (4.2) 
Transverse colon 2198 (6.2) 1542 (6.9) 
Splenic flexure 857 (2.4) 606 (2.7) 
Descending colon 1225 (3.5) 819 (3.7) 
Sigmoid colon 7639 (21.5) 5756 (25.9) 
Rectosigmoid junction 2057 (5.8) 1191 (5.4) 
Rectum 11 067 (31.2) 5526 (24.9) 
T-stage, n (%)   
1 2088 (5.9) 683 (6.1) 
2 7174 (20.2) 2118 (19.0) 
3 18 476 (52.1) 5674 (50.9) 
4 7734 (21.8) 2684 (24.1) 
N-stage, n (%)   
0 16 276 (45.9) 6600 (53.1) 
1 12 621 (35.6) 3710 (29.9) 
2/3 6575 (18.5) 2109 (17.0) 
M-stage, n (%)   
0 28 312 (79.8) 9929 (73.2) 
1 7160 (20.2) 3627 (26.8) 
Treatment intent, n (%)   
Curative 27 176 (76.6) 12 397 (67.5) 
Non-curative 6740 (19.0) 4291 (23.4) 
No active cancer treatment 1556 (4.4) 1671 (9.1) 
*Age range was 18 to 104. †Rescaled national rank of the area in which a patient resided (0 is the median; -1 is the lower quartile, more 
deprived; 1 is the upper quartile, less deprived). ‡Measured on the Eastern Cooperative Oncology Group (ECOG) scale. ED: emergency 
department; IQR: interquartile range. 
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Supplement S7. How to calculate probabilities of colorectal cancer death within 90, 180, and 365 
days of diagnosis from the prediction model 
The probability of colorectal cancer death by time t equals:  1 −  𝑆0(𝑡)
exp(𝛽1𝑋1+ 𝛽2𝑋2+ ⋯ + 𝛽𝑝𝑋𝑝). 
where S0(t) is the baseline survival probability at time t, β are the regression coefficients from the estimated Cox 
proportional hazards regression model, X are predictor variables, and p is the number of predictor variables. 
The value of S0(t) for an individual with all risk factors equal to zero** is: 
• For the 90 days period:     0.9983142 
• For the 180 days period:   0.9969342 
• For the 365 days period:   0.9941971 
The values of β for each predictor variable are: 
 β 




Socioeconomic status† -0.03625044 
Referral source  
Emergency admission 0 
Urgent care/ED visit -0.01889659 
Screening -1.09412094 
Primary care -0.31258302 
Other -0.28886696 
Performance status‡  




4 (completely disabled) 1.21503157 
Tumour site  
Caecum 0 
Ascending colon -0.08209810 
Hepatic flexure 0.13092154 
Transverse colon 0.07391412 
Splenic flexure -0.12596959 
Descending colon -0.08558521 
Sigmoid colon -0.21539719 














Treatment intent  
Curative 0 
Non-curative 1.34685236 
No active cancer treatment 1.34679083 
*Age range was 18 to 104. †Rescaled national rank of the area in which a patient resided (0 is the median; -1 is the lower quartile, more 
deprived; 1 is the upper quartile, less deprived). ‡Measured on the Eastern Cooperative Oncology Group (ECOG) scale. ED: emergency 
department. **Baseline survival probabilities assume age zero and median socioeconomic status. 
